Signaling Modulation Mediated by Ligand Water Interactions with the Sodium Site at μOR

Rohini S. Ople, Nokomis Ramos‐Gonzalez, Qiongyu Li, Briana L. Sobecks, Deniz Aydın, Alexander S. Powers, Abdelfattah Faouzi, Benjamin J. Polacco, Sarah M. Bernhard, Kevin Appourchaux, Sashrik Sribhashyam, Shainnel O. Eans, Bowen A. Tsai, Ron O. Dror, Balázs R. Varga, Haoqing Wang, Ruth Hüttenhain, Jay P. McLaughlin, Susruta MajumdarACS 2024 · DOI

TL;DR

Researchers have designed a new opioid analgesic, RO76, that targets the mu-opioid receptor (μOR) by interacting with water molecules in a key allosteric binding site. This novel approach leads to potent pain relief with significantly reduced side effects like respiratory depression and physical dependence compared to morphine, offering a promising avenue for safer pain management.

What Problem Does This Paper Address?

The mu-opioid receptor (μOR) is a critical target for pain relief, but current μOR agonists, like morphine, are associated with severe adverse effects including respiratory depression, physical dependence, and constipation. These side effects limit their therapeutic utility and contribute to the ongoing opioid crisis. Developing safer analgesics that retain efficacy while minimizing these liabilities is a major challenge in pharmacology. Previous work by the authors identified a strategy to target an allosteric sodium binding site on the μOR with a compound called C6guano, which showed promise but had limited systemic activity due to its charged nature. This paper aims to improve the systemic activity and overall profile of ligands targeting this allosteric site.

Methods

The study employed a multi-faceted approach combining structure-based drug design, synthetic chemistry, advanced structural biology, computational modeling, and in vivo pharmacology.

  • Structure-Based Design: Leveraging existing knowledge of the μOR and the previous ligand C6guano, the researchers designed new analogs by modifying the chemical structure to improve blood-brain barrier penetration and target the sodium site indirectly.
  • Synthetic Chemistry: A library of ten fentanyl analogs was synthesized to explore structure-activity relationships.
  • Cryo-Electron Microscopy (Cryo-EM): The cryo-EM structure of the lead compound RO76 bound to the μOR-G<sub>i</sub> complex was determined at 3.2 Å resolution. This provided detailed atomic-level insights into how RO76 interacts with the receptor.
  • Molecular Dynamics (MD) Simulations: MD simulations were used to further investigate the dynamic interactions between RO76 and the μOR, particularly focusing on the role of water molecules in mediating ligand-receptor binding.
  • Cell-Based Signaling Assays: Various assays, including TRUPATH and BRET-based assays, were used to characterize RO76's signaling profile across different Gα subtypes and its ability to recruit β-arrestin.
  • APEX-Based Proximity Labeling: This technique was used to map the proximal protein network around the activated μOR, providing insights into receptor trafficking and signaling pathways.
  • In Vivo Pharmacology: Mouse models were used to assess RO76's antinociceptive effects (pain relief), respiratory depression, and physical dependence potential, comparing it directly to morphine.

Datasets

Not explicitly discussed as distinct datasets for training or evaluation in the context of machine learning. The study relies on:

  • Existing μOR structures: Used as a basis for structure-based design and comparison.
  • Previously generated signaling data: For comparison with DAMGO and PZM21.
  • Newly generated experimental data: From cryo-EM, MD simulations, cell-based assays, APEX labeling, and in vivo animal studies.

Key Insights and Ideas

  • Water as a Ligand Mediator: The most significant insight is the successful targeting of the μOR allosteric sodium site indirectly through water molecules. This demonstrates a novel strategy for ligand design in GPCRs, moving beyond direct interactions with protein residues.
  • Partial Agonism for Safety: RO76 acts as a partial agonist, meaning it elicits a submaximal response even at saturating concentrations. This property is often associated with a better safety profile, particularly regarding respiratory depression.
  • Modulating β-arrestin Recruitment: The design strategy successfully reduced β-arrestin recruitment, a pathway linked to adverse effects like tolerance and dependence, while maintaining G protein signaling for analgesia.
  • Structural Basis for Reduced Efficacy: Cryo-EM and MD simulations revealed that RO76's interaction with the sodium site is water-mediated and does not involve direct engagement with key residues like Y326<sup>7.43</sup>, which is implicated in β-arrestin recruitment by other potent agonists. This lack of direct interaction with Y326<sup>7.43</sup> is hypothesized to be a key factor in RO76's reduced β-arrestin signaling.
  • APEX Reveals Distinct Trafficking: APEX labeling showed that RO76 does not induce receptor internalization or trafficking, unlike potent agonists like DAMGO, further supporting its safer profile.

Key Results

  • RO76 Design: RO76 was designed by replacing the flexible linker and polar guanidine of C6guano with a benzyl alcohol moiety, enabling indirect targeting of the sodium site via water molecules.
  • Structural Confirmation: Cryo-EM revealed RO76 binding to the μOR, with its benzyl alcohol group interacting with sodium site residues (D114<sup>2.50</sup>, S329<sup>7.46</sup>, Y326<sup>7.43</sup>) through a water molecule.
  • Signaling Profile: RO76 is a μOR-selective partial agonist with moderate potency, showing reduced β-arrestin-1/2 recruitment compared to full agonists.
  • In Vivo Efficacy and Safety: In mice, RO76 demonstrated potent antinociception comparable to morphine. Crucially, it showed significantly reduced respiratory depression and physical dependence symptoms compared to morphine at equianalgesic doses.
  • Oral Bioavailability: RO76 showed potential for oral administration, with reasonable antinociceptive effects observed.

Limitations and Future Work

  • Loss of Gα Selectivity: The authors note that the Ga subtype selectivity observed with the previous ligand C6guano was lost with RO76, suggesting that indirect engagement of the sodium site might lead to a broader G protein coupling profile.
  • Potency vs. Efficacy: While RO76 exhibits potent antinociception in vivo, its in vitro potency is lower than that of some other μOR agonists. The authors acknowledge that this discrepancy warrants further investigation, potentially related to factors like brain penetration or pharmacokinetic properties.
  • Motor Activity: At higher doses, RO76 showed limited motor activity, the reasons for which are currently unknown and require further investigation.
  • PALD1 Role: The APEX data identified the putative phosphatase Paladin 1 (PALD1) in the proximal network of activated μOR. While its specificity for RO76 is unclear, its role in μOR signaling warrants further investigation.
  • Broader GPCR Application: The authors suggest that targeting water molecules in allosteric sites could be a generalizable strategy for other GPCRs where conserved water networks exist, opening up new avenues for drug discovery.
  • Further Refinement: The authors suggest that further refinement of the ligand design could lead to even higher G protein activity.

Summary updated

Abstract

The mu opioid receptor (μOR) is a target for clinically used analgesics. However, adverse effects, such as respiratory depression and physical dependence, necessitate the development of alternative treatments. Recently we reported a novel strategy to design functionally selective opioids by targeting the sodium binding allosteric site in μOR with a supraspinally active analgesic named <b>C6guano</b>. Presently, to improve systemic activity of this ligand, we used structure-based design, identifying a new ligand named <b>RO76</b> where the flexible alkyl linker and polar guanidine guano group is swapped with a benzyl alcohol, and the sodium site is targeted indirectly through waters. A cryoEM structure of <b>RO76</b> bound to the μOR-G<sub>i</sub> complex confirmed that <b>RO76</b> interacts with the sodium site residues through a water molecule, unlike <b>C6guano</b> which engages the sodium site directly. Signaling assays coupled with APEX based proximity labeling show binding in the sodium pocket modulates receptor efficacy and trafficking. In mice, <b>RO76</b> was systemically active in tail withdrawal assays and showed reduced liabilities compared to those of morphine. In summary, we show that targeting water molecules in the sodium binding pocket may be an avenue to modulate signaling properties of opioids, and which may potentially be extended to other G-protein coupled receptors where this site is conserved.
BibTeX
@inproceedings{ople2024signaling,
  author = {Rohini S. Ople and Nokomis Ramos‐Gonzalez and Qiongyu Li and Briana L. Sobecks and Deniz Aydın and Alexander S. Powers and Abdelfattah Faouzi and Benjamin J. Polacco and Sarah M. Bernhard and Kevin Appourchaux and Sashrik Sribhashyam and Shainnel O. Eans and Bowen A. Tsai and Ron O. Dror and Balázs R. Varga and Haoqing Wang and Ruth Hüttenhain and Jay P. McLaughlin and Susruta Majumdar},
  title = {{Signaling Modulation Mediated by Ligand Water Interactions with the Sodium Site at μOR}},
  booktitle = {ACS},
  year = {2024},
  doi = {10.1021/acscentsci.4c00525},
}
Figure